Ignyta, Inc.
Ignyta, Inc. (RXDX): 4 pipeline candidates · ~17 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
17.0 months
D/E 0.75 · 0% dilution
Lead: Phase 1
4 candidates
N/A
N/A
A transparent, data-derived signal for Ignyta, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$29.6M
Quarterly Burn
$24.7M
Runway
17.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in Ignyta, Inc.'s pipeline?
Ignyta, Inc. (RXDX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Ignyta, Inc.'s lead drug candidate?
Ignyta, Inc.'s most advanced tracked candidate is rxdx-105 (Phase 1) for solid tumors.
What is Ignyta, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Ignyta, Inc. has approximately 17.0 months of cash runway.
Who is the CEO of Ignyta, Inc.?
Jonathan E. Lim, M.D. is the chief executive officer of Ignyta, Inc. (RXDX).
Get the full picture on Ignyta, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.